ERBB2 and cancer: The multinomial logistic regression results demonstrated that a growth in Perfusion-Function (i.e., blood flow at the hot spot of tumor) would lead to a rise in the odds of cancers with the worse prognostic factors such as positive lymph node metastasis, larger tumor size, hormone receptor negativity, HER2 positivity, or higher Ki67 level, and that a growth in Perfusion-Function would result in a rise in the odds of HER2 overexpressing cancer or triple negative cancer compared to luminal type cancer.